STOCK TITAN

Perceptive funds disclose 7.3% SAB Biotherapeutics (SABS) ownership

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

SAB Biotherapeutics, Inc. is the subject of a Schedule 13G showing that Perceptive Advisors LLC, its Perceptive Life Sciences Master Fund, Ltd., and Joseph Edelman collectively report beneficial ownership of 3,471,861 shares of SAB’s common stock, representing 7.3% of the class.

The Master Fund directly holds the 3,471,861 shares, and the ownership percentage is based on 47,606,851 outstanding shares as of November 10, 2025, as disclosed in SAB’s Form 10-Q. Perceptive Advisors, as investment manager, and Mr. Edelman, as managing member, share voting and dispositive power over these shares. The filers certify the position was not acquired to change or influence control of SAB Biotherapeutics.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Perceptive Advisors LLC
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:01/22/2026
Joseph Edelman
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman
Date:01/22/2026
Perceptive Life Sciences Master Fund, Ltd.
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:01/22/2026

FAQ

What stake in SAB Biotherapeutics (SABS) does Perceptive report on this Schedule 13G?

Perceptive Advisors LLC, its Perceptive Life Sciences Master Fund, Ltd., and Joseph Edelman report beneficial ownership of 3,471,861 shares of SAB Biotherapeutics common stock, representing 7.3% of the class.

Which Perceptive entity directly holds SAB Biotherapeutics (SABS) shares?

The Perceptive Life Sciences Master Fund, Ltd. directly holds 3,471,861 shares of SAB Biotherapeutics common stock, with Perceptive Advisors and Joseph Edelman deemed beneficial owners through control relationships.

How was the 7.3% ownership in SAB Biotherapeutics (SABS) calculated?

The 7.3% ownership is based on 47,606,851 outstanding shares of SAB Biotherapeutics common stock as of November 10, 2025, as reported in the company’s Form 10-Q.

Do Perceptive Advisors and Joseph Edelman control voting and disposition of SAB Biotherapeutics (SABS) shares?

Perceptive Advisors, Joseph Edelman, and the Master Fund each report 0 shares with sole voting or dispositive power and 3,471,861 shares with shared voting and dispositive power.

Is Perceptive’s SAB Biotherapeutics (SABS) position intended to influence control of the company?

The Reporting Persons certify that the securities were not acquired and are not held for the purpose of changing or influencing the control of SAB Biotherapeutics.

Who are the reporting persons on this SAB Biotherapeutics (SABS) Schedule 13G?

The reporting persons are Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd., all reporting beneficial ownership of the same share amount and percentage.
SAB BIOTHERAPEUTICS INC

NASDAQ:SABS

SABS Rankings

SABS Latest News

SABS Latest SEC Filings

SABS Stock Data

191.86M
41.72M
14.29%
18.66%
4.23%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
MIAMI BEACH